Tonix Pharmaceuticals - TNXP Stock Forecast, Price & News

Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and licensing therapeutics and diagnostics to treat and prevent human disease and alleviate suffering. Its portfolio includes immunology, rare disease, infectious disease, and central nervous system (CNS) product candidates. The company's immunology portfolio includes biologics to address organ transplant rejection, autoimmunity, and cancer, including TNX-1500, a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft and xenograft rejection and for the treatment of autoimmune diseases. Its rare disease portfolio comprises TNX-2900 for the treatment of Prader-Willi syndrome. The company's infectious disease pipeline includes TNX-801, a vaccine to prevent smallpox and monkeypox; TNX-1840 and TNX-1850 that are live virus vaccines based on its recombinant pox vaccine (RPV) platform for COVID-19; TNX-3500, a small molecule antiviral drug to treat acute COVID-19; and TNX-102 SL, a small molecule drug to treat Long COVID, a chronic post-acute COVID-19 condition. Its CNS portfolio includes small molecules and biologics to treat pain, neurologic, psychiatric, and addiction conditions, including TNX-102 SL, which is in mid-Phase 3 development for the management of fibromyalgia; TNX-1900 that is in development for the prevention of migraine headache; and TNX-1300, a biologic designed to treat cocaine intoxication. The company was founded in 2007 and is headquartered in Chatham, New Jersey.

Analysts Set New Price Targets

A number of analysts have weighed in on TNXP shares. Noble Financial began coverage on Tonix Pharmaceuticals in a report on Monday, April 18th. They set an "outperform" rating and a $19.20 target price for the company. StockNews.com raised Tonix Pharmaceuticals to a "sell" rating in a research report on Friday, August 5th.

Tonix Pharmaceuticals Stock Up 2.2 %

Shares of NASDAQ:TNXP traded up $0.03 during trading hours on Friday, hitting $1.40. 2,690,783 shares of the stock were exchanged, compared to its average volume of 15,976,027. Tonix Pharmaceuticals has a 12 month low of $1.19 and a 12 month high of $24.89. The firm has a fifty day moving average price of $1.67 and a 200-day moving average price of $4.76. The company has a market cap of $60.28 million, a PE ratio of -0.21 and a beta of 1.54.

Tonix Pharmaceuticals (NASDAQ:TNXP - Get Rating) last issued its quarterly earnings data on Monday, August 8th. The company reported ($1.22) EPS for the quarter, beating the consensus estimate of ($1.45) by $0.23. As a group, equities analysts anticipate that Tonix Pharmaceuticals will post -6.12 earnings per share for the current fiscal year.

Insider Activity at Tonix Pharmaceuticals

In other Tonix Pharmaceuticals news, CEO Seth Lederman purchased 20,000 shares of the stock in a transaction on Wednesday, June 29th. The stock was acquired at an average price of $1.71 per share, with a total value of $34,200.00. Following the completion of the acquisition, the chief executive officer now owns 24,235 shares in the company, valued at $41,441.85. The acquisition was disclosed in a filing with the SEC, which is available at this link. 1.23% of the stock is currently owned by corporate insiders.